Introduction {#s1}
============

Understanding the epidemiological features and metrics of malaria in endemic populations is a key component to monitoring and quantifying the impact of current and past control efforts to reduce morbidity due to plasmodia infection to a level that is acceptable from a public health perspective, eliminate malaria by decreasing the reproduction number (R~0~) to a level at which transmission is not sustained by local mosquito vectors in a defined geographic region, and ultimately to eradicate malaria by irrevocably reducing the global incidence of plasmodia infection to nil.[@R1] Historically, the goal of the Global Malaria Eradication Program (GMEP) initiated by the World Health Organization (WHO) in 1955 was to eliminate malaria in all endemic areas of the world with the exception of Africa, where the goal was to control malaria. Implementation of the major interventions available at the time, specifically antimalarial drugs (primarily chloroquine) to reduce infection prevalence in human populations and dichlorodiphenyltrichloroethane (DDT) to shorten mosquito vector viability, resulted in the elimination of *Plasmodium falciparum* and *P. vivax* transmission in 37 countries where these infections were endemic in 1950.[@R2] By the mid-1970s, malaria was eliminated in 27 countries of Europe and North America.[@R3] The remarkable success of the GMEP in these areas was aligned with the improvement of the local public health infrastructure, the commitment of financial and human resources that were not realized until after the Second World War, and sustained political commitment. In contrast, in many other countries where preexisting transmission was high to moderate, efforts at elimination were largely abandoned by the late 1960s because of the unanticipated development of parasite resistance to chloroquine and decreasing efficacy of DDT against mosquito vectors.

The metrics used to monitor and evaluate changes in malaria transmission at the time varied among, and even within, regions and countries.[@R4] Indicators commonly used for surveillance and monitoring included the prevalence of blood stage infection determined by the microscopic examination of blood smears, the estimated number of deaths attributed to malaria recorded by national or local health authorities, and the incidence of clinical malaria. Aside from infection diagnosed by microscopic inspection of blood smears, the sensitivity and specificity of metrics based on death and clinical manifestations attributable to plasmodia infection were unclear, particularly, in the many areas where other causes of acute febrile illness and anemia in children were common. Meaningful analyses and comparison of progress toward elimination across different endemic regions with varying malaria epidemiology was compromised given the lack of consensus on the use of a standardized and validated set of metrics.

In the wake of the abandonment of the GMEP, the prevalence of infection and malaria-related deaths increased in Africa and other areas where transmission was sustained. Because of the increasing number of children and pregnant women in Africa who experienced malaria morbidity and death during the past decades of the twentieth century, the WHO created the Roll Back Malaria program.[@R5] Launched in 1998, the program was based primarily on the deployment of artemisinin combination therapy (ACT), distribution of insecticide-treated bed nets (ITNs) and to a lesser extent, indoor residual spraying (IRS) of insecticide.[@R6] More recently, the changing epidemiology of *P. falciparum* malaria in Africa was assessed from 2000 to 2010, the time period over which these interventions were implemented.[@R7] Using published and publically available data from throughout the region, spatial and temporal trends of *P. falciparum* infection were analyzed among 2- to 10-year-old children (PR*Pf*~2--10~) as an indicator of transmission. Downward trends in *P. falciparum* transmission were noted in many areas. However, a major conclusion of this comprehensive analysis was that 57% of African residents continued to live in areas where transmission was moderate to high in 2010.

What do these not-so-recent and recent reports of malaria epidemiology mean in the context of the National Institutes of Health International Centers of Excellence for Malaria Research (ICEMR) effort, now in the fourth year since its inception? The ICEMR program was created in a new era with a goal that goes beyond malaria "control," an era in which eradication has been put back on the table as an achievable goal that might benefit the generation of children born in endemic areas today.[@R8] Knowledge of the cell biology, genetics, genomics, and biochemistry of the parasite, particularly in the case of *P. falciparum* but less in *P. vivax* (the other major *Plasmodium* species important to human health), has advanced remarkably over the past several decades. Equally important, point-of-care diagnostic tests for blood stage infection (i.e., rapid diagnostic tests \[RDTs\]) and highly sensitive polymerase chain reaction assays that detect low-density blood stage infections that may sustain transmission of infection from humans to mosquitos[@R9] are widely used. In addition, antimalarial regimens such as ACTs and wide deployment of ITNs appear to have reduced morbidity and allowed significant progress toward elimination in low transmission settings such as the Solomon Islands and Vanuatu.[@R10] The ICEMR program thus has the opportunity to evaluate the impact of these and future interventions across endemic regions, which differ in the dominant *Plasmodium* species, mosquito vector species, resistance to antimalarial drugs, and human genetic variants thought to confer protection from infection and clinical manifestations of malaria. These evaluations can be conducted in greater depth than routinely done by national malaria control programs, including detailed molecular analyses of parasites and vectors and more sophisticated spatial analyses, albeit in more limited geographical areas.

There now exist not only historically used metrics to monitor and evaluate the impact of interventions to control and eliminate malaria, such as infection and malaria attributable disease prevalence and deaths, but also highly sensitive molecular and genetic tools that reflect subtle changes in the epidemiology and transmission dynamics of *P. falciparum* and *P. vivax* ([Table 1](#T1){ref-type="table"} ). For example, the impact of key interventions such as population coverage with (ITNs), IRS, and case management can be mapped and tracked using newer metrics such as the force of infection[@R11] (the number of new infections per person per unit time as determined by molecular genotyping to quantify exposure to new *Plasmodium* clones over time) and seroconversion rate (calculated by fitting a reverse catalytic model to age-specific prevalence of antibody responses to a single or defined set of recombinant malaria proteins expressed by various stage of the parasite lifecycle). The following sections describe how the ICEMR program represents a unique opportunity to compare the validity and utility of these and other newly developed metrics of transmission intensity and clinically relevant indicators that can be used in a standardized manner across the major malaria-endemic areas of the world to evaluate and guide malaria control and elimination strategies.

ICEMR Field Studies of Malaria Surveillance, Monitoring, and Evaluation {#s2}
=======================================================================

Given the diverse and evolving nature of malaria transmission and its clinical manifestations, it is critical to generate basic epidemiological information across a range of settings. The ICEMR programs are uniquely positioned to capture this shifting epidemiology in real time across the globe. All ICEMR programs are conducting field studies at multiple sites with the aim of generating surveillance data to improve understanding of malaria transmission and to monitor and evaluate the impact of interventions to inform malaria control and elimination programs. In addition, these epidemiological studies provide a vast source of biological samples linked to clinical and environmental "meta-data" to support translational studies of interactions between the parasite, human host, and mosquito vector. The basic types of epidemiological studies being conducted by the ICEMR programs are described, with a focus on methodological issues, types of malaria indicators generated, and the strengths and weakness of each study design ([Table 2](#T2){ref-type="table"}).

Health facility-based surveillance. {#s2a}
-----------------------------------

ICEMR field activities can be divided into four general categories: health facility-based surveillance, cohort studies, cross-sectional surveys, and entomological surveys. Health facility-based surveillance provides an efficient means of collecting basic epidemiological data on large numbers of patients presenting to health centers. These data are generally part of a country's routine health management information systems and are one of the main sources of data reported to the WHO and Roll Back Malaria.[@R12] Data collected from health facility-based surveillance include the number of symptomatic patients with suspected malaria, numbers of cases receiving a diagnostic test, the number of confirmed malaria cases, and the number of malaria deaths. Indicators used include the test positivity rate (the proportion of patients with suspected malaria who are tested for infection and test positive), malaria case incidence (i.e., confirmed malaria cases per 1,000 persons per year), and malaria mortality rate (inpatient malaria deaths per 100,000 persons per year). The primary advantage of health facility-based surveillance data is the relative ease of collecting longitudinal data on a large number of patients at different spatial scales, up to the national level. The primary disadvantages of health facility-based data is that it is often incomplete and of poor quality, limited by variation in health-seeking behaviors, and fails to capture asymptomatic and subpatent infections. Many patients may not present to the formal health-care system and even when they do, diagnostic testing for malaria is often not performed or is inaccurate. Indeed, malaria case detection rates captured through health facility-based surveillance systems are lowest in countries with the highest estimated burden of malaria.[@R12] Caution should be taken in the interpretation of temporal trends in malaria metrics derived from health facility-based surveillance due to changes in health-seeking behavior; case definitions; the utilization, methods (i.e., microscopy versus RDT), availability and quality of laboratory diagnostic testing used; and the rates and accuracy of reporting. All of the ICEMR programs are conducting health facility-based surveillance at a range of outpatient and inpatient facilities, usually in collaboration with local governments. Advantages to some of these ICEMR-affiliated facilities are that additional resources are being applied to improve the quality and timeliness of data through standardized approaches to diagnostic testing, quality control measures, reliance on laboratory confirmed cases, and the use of electronic records and short message service text messages.

Cohort studies. {#s2b}
---------------

Cohort studies are generally considered the gold standard for estimating the burden of malaria in a defined population. These studies involve following a group of study participants (ideally representative of the target population of interest) over time with a combination of active and passive surveillance activities to measure a variety of malaria indicators. Common indicators include malaria incidence, period prevalence of parasitemia and anemia, and force of infection (definitions provided in [Table 1](#T1){ref-type="table"}). The primary advantages of cohort studies are the high quality and breadth of data that can be generated. A well-conducted cohort study has the ability to accurately capture all malaria cases (both clinical and subclinical) and person-time at risk, necessary requirements for estimating incidence measures and temporal changes. Cohort studies can be used to estimate the impact of population level interventions and are a rich source of biological samples linked to a variety of other "meta-data." The primary disadvantages of cohort studies are they are expensive and logistically challenging to conduct. In addition, data from cohorts may not be generalizable due to their sampling frame, changes in the composition of the cohort over time, and the fact that the cohort study itself may influence outcomes (for example, the need to treat all participants diagnosed with malaria and improved access to medical care). In low transmission settings, the incidence of malaria may be too low to justify the use of a cohort study design. Historically, many high-quality cohort studies, such as the Garki Project,[@R13] were conducted in high transmission settings with fewer focusing on malaria across a range of epidemiological settings. The ICEMR programs are addressing this gap by conducting cohort studies over extended periods in numerous sites around the globe. These studies should provide a wealth of contemporary descriptive data, which will be strengthened by efforts to standardize methodologies and metrics, combine datasets, share biological samples for translational studies, and develop novel interactive data management tools for exploring these rich and complex datasets.

Cross-sectional surveys. {#s2c}
------------------------

Cross-sectional surveys provide another common source of data used for malaria surveillance and monitoring and evaluation. Cross-sectional surveys generally involve administration of a questionnaire and the collection of blood samples from members of households selected using probability sampling. Common indicators generated from cross-sectional surveys include coverage levels of preventive interventions (ITNs and IRS), fever case management practices, health-seeking behaviors, health status (under five mortality rate and anemia), and parasite prevalence for clinical and subclinical malaria (definitions provided in [Table 1](#T1){ref-type="table"}). Examples of national cross-sectional surveys include Demographic Health Surveys and Malaria Indicator Surveys. These data are commonly used by the WHO and Roll Back Malaria as well for malaria risk mapping, such as that done by the Malaria Atlas Project.[@R14] Advantages of cross-sectional surveys are they are relatively easy to do, provide a large amount of information, and are generally representative of the population. However, they are relatively expensive and not performed frequently. Disadvantages of cross-sectional surveys include limited ability to capture data on malaria morbidity and monitor trends over shorter periods or on a fine spatial scale. All of the ICEMR programs are conducting cross-sectional surveys. Most of these surveys are being conducted repeatedly in defined geographic areas where other field activities are being carried out concurrently, such as entomological surveys. These approaches should improve our understanding of the relationships between indicators derived from different study designs and estimate the impact of changes in the coverage levels of control interventions with clinically relevant indicators measured longitudinally.

Entomological surveys. {#s2d}
----------------------

Entomological surveys comprise a broad range of methodologies aimed at generating data on the mosquito vector and its interaction with the human host. Methods commonly used to collect mosquitoes include human landing catches, Centers for Disease Control and Prevention light traps, pyrethrum spray catches, exit traps, household aspiration, screen barriers, and Shannon traps. Collection methods are based on the resting and biting behaviors of different *Anopheles* species. Once mosquitoes are collected, a variety of methods can be used for species identification, identifying sources of blood meals, and determining if the mosquito is infected with various stages of the malaria parasite. Commonly used indicators of transmission intensity include the human biting rate, the sporozoite rate, and the entomological inoculation rate (EIR). The advantages of entomological surveys are they can provide a rich source of data and the only direct measures of transmission. The primary disadvantage of entomological surveys is the lack of standardization in methods used to collect and interpret data, as well as the limitations of collection methods to capture mosquitoes feeding outdoors or during the day. Estimates of indicators derived from entomological surveys may be limited by precision and accuracy and lack the ability to discriminate small-scale spatial or temporal variability. This is especially true in low transmission settings where it may not be possible to collect sufficient numbers of mosquitoes or detect sporozoites. Entomology surveys are generally not done outside of the research setting due to logistical challenges and the need for specialized equipment, training, and expertise. All of the ICEMR programs are conducting some variation of entomological surveys. The methods used vary widely, largely because of differences in the local environments, characteristics of predominant vectors, and prior experience. Efforts are ongoing to standardize protocols, reagents, and analytical methods across the ICEMR programs. Information gained from these entomological surveys will fill a knowledge gap and improve the quality of these data so critical to improve our understanding of malaria transmission dynamics.

Key Malaria Metrics at ICEMR Research Sites {#s3}
===========================================

All four major parasite species infecting humans are represented in the ICEMR research sites (*Plasmodium knowlesii* is not a predominant parasite species at any ICEMR research site) ([Table 3](#T3){ref-type="table"}, [Figure 1](#F1){ref-type="fig"} Figure 1.Predominant parasite species at the International Centers of Excellence for Malaria Research (ICEMR) research sites.). As expected, *Plasmodium falciparum* is the predominant parasite species at the 13 ICEMR research sites in Africa, with *P. vivax* and *P. falciparum* found throughout ICEMR research sites in South America and Asia. All four major parasite species are transmitted within ICEMR research sites in Papua New Guinea and southeast Asia.

Malaria transmission intensity as measured by the annual EIR varies widely across ICEMR research sites, ranging from below one infectious bite per year at sites in southeast Asia, Nadiad in India, Buenaventura in Colombia, Sullana in Peru, and Choma District in Zambia to 310 infectious bites per year in Tororo, Uganda ([Table 3](#T3){ref-type="table"}, [Figure 2](#F2){ref-type="fig"} Figure 2.Approximate annual entomological inoculation rates at International Centers of Excellence for Malaria Research (ICEMR) research sites.). These differences reflect variation in major vector species, abundance, breeding habitats, and feeding behaviors as well as differences in the methods used to estimate EIR. Seasonal differences also determine malaria transmission intensity and vary across ICEMR sites ([Table 3](#T3){ref-type="table"}, [Figure 3](#F3){ref-type="fig"} Figure 3.Seasonality of malaria transmission at the International Centers of Excellence for Malaria Research (ICEMR) research sites.). Both transmission intensity and seasonal patterns determine the interventions needed to achieve control or elimination. The parasite prevalence varies widely across ICEMR sites, from less than 1% in regions moving toward elimination to as high as 60% in Tororo, Uganda ([Table 3](#T3){ref-type="table"}, [Figure 4](#F4){ref-type="fig"} Figure 4.Approximate parasite prevalence at the International Centers of Excellence for Malaria Research (ICEMR) research sites.).

The ICEMR field sites reflect the range of commonly used malaria control interventions. Although the ICEMR investigators are not engaged in implementing malaria control interventions, the ICEMR field sites provide a platform to evaluate the effectiveness of current and future interventions implemented by national control programs. RDTs and artemisinin combination therapies are used for case management at many ICEMR sites. Malaria is confirmed by microscopy at ICEMR sites in Latin America and India. Intermittent presumptive treatment of malaria in pregnancy is used at ICEMR sites in sub-Saharan Africa and the southwest Pacific but not at sites in Latin America or India, where the combination of chloroquine and primaquine is used to treat disease due to *P. vivax* (with the exception of pregnant women). Reactive case detection, in which individuals residing within a define radius of a symptomatic index case are tested and treated for malaria, is conducted by the national malaria control programs in low transmission settings at ICEMR sites in Mali, Zambia, and southeast Asia that are moving toward elimination, as well as in Colombia for urban malaria elimination. For vector control, ITNs are distributed at almost all ICEMR sites but with varying levels of coverage ([Table 3](#T3){ref-type="table"}), and IRS is used at ICEMR sites in east and southern Africa and at some sites in India, southeast Asia, and southwest Pacific ([Table 3](#T3){ref-type="table"}).

Discussion {#s4}
==========

The epidemiology of malaria is heterogeneous and highly focal, representing a diversity of parasites, vectors, seasonal patterns, and transmission intensities.[@R15] Strategies for control and elimination must be adapted to the local epidemiological and entomological conditions. The ICEMR research sites represent this range of epidemiological diversity across tropical and subtropical regions in four continents. Even at smaller spatial scales, within countries, provinces and districts, the epidemiology of malaria can be widely diverse, as exemplified by ICEMR research sites in Uganda, Malawi, and Zambia. Comparisons of the impact of malaria control interventions across a range of epidemiological settings are possible using standardized metrics for a given intervention (such as coverage with insecticidal net distribution) and simple or sophisticated measures of transmission intensity (such as force of infection). The range of epidemiological settings encompass areas where *P. vivax* or *P. falciparum* predominate or where mosquito vectors seek blood meals indoors at night or outdoors during early evening. Importantly, epidemiological studies at the ICEMR field sites are integrated with entomological studies, including measurement of the EIR, human biting index, and insecticide resistance, as well as studies of parasite genetic diversity and antimalarial drug resistance. These integrated studies will lead to more detailed and richer understandings of malaria transmission dynamics across the range of epidemiological settings than can be accomplished through studies of only one of these domains. Furthermore, this platform provides the framework for novel studies of malaria epidemiology, including cross-ICEMR investigations of serological responses to an array of parasite antigens and detailed studies of population movement. Epidemiological studies at ICEMR sites will provide a deeper understanding of why specific interventions succeed or fail and will identify surveillance strategies that can be incorporated into standard practice and are sensitive to changes in key malaria indicators.
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###### 

Summary of key indicators used for malaria monitoring and evaluation and surveillance

  Category                                                                                         Indicators                                                                                                                               Definitions                                                                                    Primary source of data                                    
  ------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------
  Key control interventions                                                                        ITN coverage                                                                                                                             Proportion of households with at least one ITN                                                 Household surveys                                         
  Proportion of households with at least one ITN for every two people                                                                                                                                                                                                                                                                                                                                
  Proportion of proportion of individuals reporting ITN use in previous night                                                                                                                                                                                                                                                                                                                        
  IRS coverage                                                                                     Proportion of households sprayed with IRS within the last 12 months                                                                                                                                                                                                                               
  Proportion of population protected by IRS within the last 12 months                                                                                                                                                                                                                                                                                                                                
  Case management                                                                                  Proportion of suspected malaria cases that receive a parasitological test                                                                                                                                                                                                                         
  Proportion of confirmed malaria cases that receive first-line therapy                                                                                                                                                                                                                                                                                                                              
                                                                                                   IPTp coverage                                                                                                                            Proportion of women who received at least three or more doses of IPTp during last pregnancy                                                              
  Category                                                                                         Indicators                                                                                                                               Definitions                                                                                    Comments                                                  Primary source of data
  Measures of transmission intensity                                                               EIR                                                                                                                                      Number of infectious bites received per person per unit time                                   Widely considered gold standard measure of transmission   Entomology surveys
  Infrequently measured                                                                                                                                                                                                                                                                                                                                                                              
  Questions about precision and accuracy                                                                                                                                                                                                                                                                                                                                                             
  Parasite rate                                                                                    Proportion of population found to carry asexual parasites                                                                                Reflection of intensity of transmission, immunity, and effectiveness of treatment              Cross-sectional surveys                                   
  Dependent on age and diagnostic method                                                                                                                                                                                                                                                                                                                                                             
  Force of infection                                                                               Number of new infections per person per unit time                                                                                        Difficult to accurately measure incident events                                                Cohort studies                                            
  Molecular techniques have been proposed as a means of quantifying new parasite clones acquired                                                                                                                                                                                                                                                                                                     
  Seroprevalence                                                                                   Proportion of population found to have a positive antibody response to a specific antigen(s)                                             Have been correlated with EIR                                                                  Cross-sectional surveys                                   
  Can provide "snap shot" of historical changes                                                                                                                                                                                                                                                                                                                                                      
  Only a limited number of antigens have been evaluated                                                                                                                                                                                                                                                                                                                                              
  Lack of standardization in methods used to collect and analyze data                                                                                                                                                                                                                                                                                                                                
  Seroconversion rate                                                                              Number of new seroconversions per person per unit time. Calculated by fitting a reverse catalytic model to age-specific seroprevalence                                                                                                                                                            
  Clinically relevant indicators                                                                   Test positivity rate                                                                                                                     Proportion of patients with suspected malaria who are tested for infection and test positive   Efficient source of longitudinal data                     Health facility-based surveillance
  Dependent on age and diagnostic methods                                                                                                                                                                                                                                                                                                                                                            
  Malaria incidence                                                                                Number of confirmed malaria cases per person time of observation                                                                         Influenced by case detection methods                                                           Cohort studies or national surveillance systems           
  Challenging to accurately measure                                                                                                                                                                                                                                                                                                                                                                  
  Subject to misclassification                                                                                                                                                                                                                                                                                                                                                                       
  Dependent on age and diagnostic methods                                                                                                                                                                                                                                                                                                                                                            
  Prevalence of anemia                                                                             Proportion of population with hemoglobin level below various thresholds                                                                  Efficient means of estimating burden of disease                                                Cross-sectional surveys                                   
  Multifactorial causes of anemia limits use                                                                                                                                                                                                                                                                                                                                                         
  Dependent on age                                                                                                                                                                                                                                                                                                                                                                                   
  All cause under 5 mortality rate                                                                 Probability (expressed as a rate per 1,000 live births) of a child born in a specified year dying before reaching the age of five        May be useful for monitoring temporal trends                                                   National surveillance systems                             
  Limited by general lack of information on causes of death                                                                                                                                                                                                                                                                                                                                          
  Malaria case fatality rate                                                                       Proportion of malaria cases that result in death                                                                                         Generally limited to inpatient setting/severe disease                                          Health facility-based surveillance                        
  Influenced by source population and quality of care                                                                                                                                                                                                                                                                                                                                                
  Death may be multifactorial                                                                                                                                                                                                                                                                                                                                                                        

EIR = entomological inoculation rate; IPTp = intermittent preventive treatment in pregnancy; IRS = indoor residual spraying; ITN = insecticide-treated bed net.

###### 

Description of ongoing or planned at ICEMR field activities of malaria surveillance, monitoring, and evaluation

  ICMER regional centers                                               Field activities                                                                                                                                                                            
  -------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------ ----------------------------------------------------------- -----------------------------------------------------------------------------------------------
  Malawi[\*](#TFN3){ref-type="table-fn"}                               2 district hospitals (outpatients and inpatients)                        1 high transmission site                               3 sites                                                     Samples collected from cross-sectional surveys, case--control study and environmental surveys
  1 urban health center (outpatients)                                  Ages 1--50 years                                                         300 households per site                                CDC light traps, household aspiration, larval collections   
  1 referral hospital (inpatients)                                     200 participants                                                         Twice a year                                                                                                       
  Active follow up every month                                         --                                                                                                                                                                                          
  West Africa                                                          4 community health centers (outpatients)                                 4 sites (3 rural, 1 urban)                             4 sites                                                     4 sites
  All ages                                                             Embedded in the cohort studies                                           2 weeks before cross-sectional surveys and midseason                                                               
  700--1,500 participants per site                                     Twice a year (beginning and end of transmission season)                  30 houses per site                                                                                                 
  PCD and active follow-up every month                                 HLC, PSC                                                                                                                                                                                    
  Southern Africa                                                      68 health centers (outpatients)                                          3 rural sites                                          3 sites                                                     3 sites
  All ages                                                             150 households per site                                                  Monthly collections                                                                                                
  430 participants                                                     Every other month                                                        175 households per site                                                                                            
  Active follow-up every 2 months                                      CDC light traps, PSC, larval collections                                                                                                                                                    
  East Africa                                                          24 health centers (outpatients)                                          3 sites (2 rural, 1 peri-urban)                        3 sites                                                     3 sites
  6 district hospitals (inpatients; children only)                     Ages 0.5--10 years and 1 adult per house                                 200 households per site                                Monthly collections                                         
  100 households per site                                              Once a year                                                              100 houses per site                                                                                                
  PCD and active follow-up every 3 months                              CDC light traps (all); HLC, PSC/exit traps (subset)                                                                                                                                         
  Amazonia                                                             2 health centers (outpatients)                                           2 sites                                                To be designed                                              6 sites
  Ages ≥ 3 years                                                       HLC, Shannon trap, screen barriers, CDC light traps                                                                                                                                         
  2,000 participants                                                   Monthly collections (rainy season)/bimonthly (dry season)                                                                                                                                   
  Active follow-up every month                                                                                                                                                                                                                                     
  Latin America                                                        4 outpatient clinics                                                     4 sites                                                5 sites                                                     8 sites with repeated collections **(**8 houses per site)
  3 hospitals (inpatients)                                             All ages                                                                 250--460 households per site                           57 sites with single collection (274 houses)                
  1,750 participants                                                   CDC light traps, HLC, PSC, larval collections                                                                                                                                               
  Active follow-up every 6 months                                                                                                                                                                                                                                  
  South Asia                                                           2 state and 1 district referral hospitals (outpatients and inpatients)   To be designed                                         To be designed                                              4 sites
  6 rural clinics (outpatients)                                        Weekly collections                                                                                                                                                                          
  CDC light traps                                                                                                                                                                                                                                                  
  India[\*](#TFN3){ref-type="table-fn"}                                3 outpatient clinic sites                                                2 sites                                                3 sites                                                     2 sites
  Ages 1--70 years                                                     200--300 participants per site                                           Monthly collections                                                                                                
  200--300 participants per site                                       Two or three times a year                                                5--20 houses; 5--18 cattle sheds depending on site                                                                 
  Active follow-up every 3 months and fortnightly fever surveillance   Aspiration and PSC; larval catches                                                                                                                                                          
  Southeast Asia                                                       86 outpatient clinics/hospitals                                          12 sites                                               12 sites                                                    3 sites
  All ages                                                             ∼150 households per site                                                 Collections twice a month                                                                                          
  Total of ∼5,400 participants                                         3--4 times a year                                                        30--60 houses per site                                                                                             
  Weekly household visits                                              Light traps                                                                                                                                                                                 
  Southwestern Pacific                                                 5 clinic sites (outpatients)                                             3 sites                                                3 sites                                                     5 sites
  Ages 0.5--12 years                                                   2,500 participants per site                                              Landing catch and barrier screen methods                                                                           
  450--800 participants per site                                       Once a year                                                                                                                                                                                 
  Active follow up every month                                                                                                                                                                                                                                     

CDC = Centers for Disease Control and Prevention; HLC = human landing catches; ICEMR = International Centers of Excellence for Malaria Research; PCD = passive case detection; PSC = pyrethrum spray catches.

Miscellaneous work includes case--control study of urban malaria (Malawi), reactive case detection (India).

###### 

Key malaria metrics at ICEMR field sites

  ICMER                      Country                          Site                 Predominant parasites     Predominant vectors       Season       EIR                            Parasite prevalence   ITN coverage (%)   IRS coverage (%)
  -------------------------- -------------------------------- -------------------- ------------------------- ------------------------- ------------ ------------------------------ --------------------- ------------------ ------------------
  Africa                                                                                                                                                                                                                    
  East Africa                Uganda                           Jinja                *Plasmodium falciparum*   *Anopheles arabiensis*    Perennial    3                              16% (2--10 years)     58                 3
  *Anopheles gambiae* s.s.                                                                                                                                                                                                  
  Uganda                     Kanungu                          *P. falciparum*      *An. gambiae* s.s.        Perennial                 30           18% (2--10 years)              51                    0                  
  Uganda                     Tororo                           *P. falciparum*      *An. gambiae* s.s.        Perennial                 310          60% (2--10 years)              79                    0                  
  Malawi                     Malawi                           Blantyre             *P. falciparum*           *Anopheles funestus*      Single       NA                             9% (all ages)         84                 2
  *An. arabiensis*                                                                                                                                                                                                          
  Malawi                     Thyolo                           *P. falciparum*      *An. funestus*            Single                    NA           14% (all ages)                 85                    0                  
  *An. arabiensis*                                                                                                                                                                                                          
  Malawi                     Chikwawa                         *P. falciparum*      *An. funestus*            Perennial                 100          30% (all ages)                 93                    73                 
  *An. arabiensis*                                                                                                                                                                                                          
  *An. gambiae* s.s                                                                                                                                                                                                         
  Southern Africa            Zambia                           Nchelenge            *P. falciparum*           *An. funestus*            Perennial    140                            50% (all ages)        62                 28
  *An. gambiae*                                                                                                                                                                                                             
  Zambia                     Choma                            *P. falciparum*      *An. arabiensis*          Single                    \< 1         1% (all ages)                  83                    0                  
  Zimbabwe                   Mutasa                           *P. falciparum*      *An. funestus*            Single                    10           10% (all ages)                 59                    57                 
  *An. gambiae*                                                                                                                                                                                                             
  West Africa                Gambia                           Gambissara           *P. falciparum*           *An. arabiensis*          Single       25                             8% (all ages)         85                 95
  *An. gambiae*                                                                                                                                                                                                             
  Senegal                    Thiès                            *P. falciparum*      *An. funestus*            Single                    1            1% (all ages)                  20                    0                  
  *An. arabiensis*                                                                                                                                                                                                          
  *An. gambiae*                                                                                                                                                                                                             
  Mali                       Dangassa                         *P. falciparum*      *An. gambiae*             Single                    50           48% (all ages)                 30                    0                  
  *An. arabiensis*                                                                                                                                                                                                          
  *An. funestus*                                                                                                                                                                                                            
  Mali                       Dioro                            *P. falciparum*      *An. gambiae*             Single                    5            24% (all ages)                 95%                   0                  
  *An. arabiensis*                                                                                                                                                                                                          
  *An. funestus*                                                                                                                                                                                                            
  South America                                                                                                                                                                                                             
  Amazonia                   Peru                             Loreto               *Plasmodium vivax*        *Anopheles darlingi*      Perennial    5                              9% (all ages)         70                 55
  *P. falciparum*                                                                                                                                                                                                           
  Latin America              Colombia                         Tierralta            *P. vivax*                *Anopheles nuneztovari*   Perennial    3                              6% (all ages)         88                 0
  *P. falciparum*            *An. darling*                                                                                                                                                                                  
  *Anopheles albimanus*                                                                                                                                                                                                     
  Colombia                   Buenaventura                     *P. vivax*           *An. nuneztovari*         Perennial                 \< 1         5% (all ages)                  95                    0                  
  *P. falciparum*            *Anopheles pseudopunctipennis*                                                                                                                                                                 
  *An. albimanus*                                                                                                                                                                                                           
  Colombia                   Tumaco                           *P. vivax*           *An. albimanus*           Perennial                 3            6% (all ages)                  97                    0                  
  *P. falciparum*            *An. calderoni*                                                                                                                                                                                
  Peru                       Sullana                          *P. vivax*           *An. albimanus*           Single                    \< 1         1% (all ages)                  44                    80                 
  *P. falciparum*                                                                                                                                                                                                           
  Asia and South Pacific                                                                                                                                                                                                    
  India                      India                            Chennai              *P. vivax*                *An. stephensi*           Perennial    NA                             5.7% *P. vivax*       0                  0
  *P. falciparum*            0.4% *P. falciparum*                                                                                                                                                                           
  India                      Raurkela                         *P. vivax*           *An. fluviatilis*         Perennial                 7.3--127     1.5% *P. vivax*                60                    5                  
  *P. falciparum*            *An. culicifacies*               5% *P. falciparum*                                                                                                                                            
  *P. malariae*                                                                                                                                                                                                             
  India                      Nadiad                           *P. vivax*           *An. culicifacies*        Single                    0.05--0.21   5.7% *P. vivax*                1                     9                  
  *P. falciparum*            2.4% *P. falciparum*                                                                                                                                                                           
  South Asia                 India                            Goa                  *P. falciparum*           *An. stephensi*           Perennial    2.5                            0.4%                  0                  0
  *P. vivax*                                                                                                                                                                                                                
  India                      Wardha                           *P. falciparum*      *An. culicifacies*        Perennial                 NA           0.2%                           0                     0                  
  *P. vivax*                                                                                                                                                                                                                
  India                      Ranchi                           *P. falciparum*      *An. culicifacies*        Perennial                 NA           1.4%                           NA                    NA                 
  *P. vivax*                 *An. fluviatilis*                                                                                                                                                                              
  India                      Assam                            *P. falciparum*      *An. baimaii*             Perennial                 0.4          6% (all ages)                  79                    40                 
  *P. vivax*                 *An. minimus*                    0.1                                                                                                                                                           
  *Plasmodium ovale*                                                                                                                                                                                                        
  *Plasmodium malariae*                                                                                                                                                                                                     
  Southeast Asia             China                            Ying Jiang           *P. vivax*                *An. minimus*             Perennial    0.1                            NA                    80                 100
  *P. falciparum*            *An. maculatus*                                                                                                                                                                                
                             *An. sinensis*                                                                                                                                                                                 
  Myanmar                    Laiza                            *P. vivax*           *An. minimus*             Perennial                 0.4          1% (all ages)                  96                    100                
  *P. falciparum*            *An. maculatus*                                                                                                                                                                                
  *An. culicifacies*                                                                                                                                                                                                        
  Thailand                   Tha Song Yang                    *P. vivax*           *An. minimus*             Perennial                 0.3          0.3% (all ages)                90                    72                 
  *P. falciparum*            *An. maculatus*                                                                                                                                                                                
  *An. annularis*                                                                                                                                                                                                           
  Southwest Pacific          PNG                              East Sepik           *P. falciparum*           *An. punctulatus*         Perennial    14                             7% *P. falciparum*    96                 0
  *P. vivax*                 *An. farauti*                    4% *P. vivax*                                                                                                                                                 
  *P. ovale*                 *An. koliensis*                  1% *P. malariae*                                                                                                                                              
  *P. malariae*              1% *P. ovale*                                                                                                                                                                                  
  (all ages)                                                                                                                                                                                                                
  PNG                        Madang                           *P. falciparum*      *An. punctulatus*         Perennial                 40           19% *P. falciparum*            96                    0                  
  *P. vivax*                 *An. farauti*                    13% *P. vivax*                                                                                                                                                
  *P. ovale*                 *An. koliensis*                  --                                                                                                                                                            
  *P. malariae*              --                                                                                                                                                                                             
  Solomon Islands            Central Province                 *P. vivax*           *An. farauti*             Perennial                 40           14% *P. vivax* (1--80 years)   90                    81                 
  *P. falciparum*                                                                                                                                                                                                           
  Solomon Islands            Western Province                 *P. vivax*           *An. farauti*             Perennial                 NA           NA                             95                    NA                 

EIR = entomological inoculation rate (number of infectious bites per year); ICEMR = International Centers of Excellence for Malaria Research; IRS = indoor residual spraying; ITN = insecticide-treated bed net; ITN coverage = proportion of households with at least two ITNs; IRS coverage = proportion of households sprayed within insecticide within the past year; NA = not available; Parasite prevalence = proportion of individuals in specified age groups positive for malaria by RDT or microscopy; PNG = Papua New Guinea; PPY = person per year.
